Price gouging is not in Aspenβs DNA, says founder Stephen Saad, incensed at the thought that his company would exploit the sick. But Aspenβs predicament, and that of all drug firms, boils down to the tension between a drug companyβs perceived responsibility to provide life-saving drugs to patients at a reasonable price, and its natural… Continue reading Financial Mail cover story – 22 June 2017